Title

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.

Authors

Vivek Subbiah
Mini I-Nan Hu
Justin F. Gainor
Aaron Scott Mansfield
Guzman Alonso
Matthew H Taylor, Providence St. Joseph HealthFollow
Viola Weijia Zhu
Pilar Garrido Lopez
Alessio Amatu
Robert C. Doebele
Philippe Alexandre Cassier
Bhumsuk Keam
Martin H. Schuler
Hui Zhang
Corinne Clifford
Michael Palmer
Jennifer Green
Christopher D. Turner
Giuseppe Curigliano

Document Type

Article

Publication Date

5-25-2020

Publication Title

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical Institute

Cancer

Department

Earle A. Chiles Research Institute

Department

Oncology

Recommended Citation

Subbiah, Vivek; Hu, Mini I-Nan; Gainor, Justin F.; Mansfield, Aaron Scott; Alonso, Guzman; Taylor, Matthew H; Zhu, Viola Weijia; Lopez, Pilar Garrido; Amatu, Alessio; Doebele, Robert C.; Cassier, Philippe Alexandre; Keam, Bhumsuk; Schuler, Martin H.; Zhang, Hui; Clifford, Corinne; Palmer, Michael; Green, Jennifer; Turner, Christopher D.; and Curigliano, Giuseppe, "Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors." (2020). Articles, Abstracts, and Reports. 3761.
https://digitalcommons.providence.org/publications/3761